Sri Kosaraju, Director at 10x Genomics, Inc.. Biography, career history and compensation sourced from SEC proxy filings.
About
Sri Kosaraju has served on the 10x Genomics board of directors since April 2019.
Since January 2026 he has served as a global chair of investment banking for JPMorgan Chase & Co. supporting the firm's healthcare industry vertical. He was President and CEO of Inscripta from October 2020 to April 2025, when it merged with Manus Bio. Earlier he was President of Penumbra (August 2019-May 2020), its CFO (May 2015-November 2019) and Head of Strategy, and before that spent 16 years in investment banking at J.P. Morgan, ultimately as Managing Director of Equity Capital Markets and Head of Healthcare Equity Capital Markets.
He received a B.S. from the Massachusetts Institute of Technology in 1999.
Roles
10x Genomics, Inc.
Director · Current role
2019–present
Inscripta
President and Chief Executive Officer · Merged with Manus Bio in April 2025.
October 2020 - April 2025
Penumbra
President · Publicly traded medical device company.
August 2019 - May 2020
Penumbra
Chief Financial Officer
May 2015 - November 2019
Penumbra
Head of Strategy
May 2015 - August 2019
J.P. Morgan Securities LLC
Investment banking, including Managing Director of Equity Capital Markets and Head of Healthcare Equity Capital Markets · Equity Capital Markets group from 2006; Equity Derivatives 2003-2006; Technology, Media, Telecom Investment Banking Coverage 1999-2003.
1999 - May 2015
External Roles
JPMorgan Chase & Co.
Global chair of investment banking (healthcare vertical)